Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

Fig. 1

a–f Selected pharmacokinetics of 213Bi-DOTATATE from Tables 1 and 2. 213Bi-DOTATATE pharmacokinetics in H69 tumour-bearing mice, uptake in tumours (a) and kidney (b), and radioactivity in blood (c) are shown over time in H69 tumour-bearing animals. Same data are shown for CA20948 tumour-bearing animals: uptake in tumours (d) and kidneys (e) and radioactivity in blood (f). Solid curves show the mean uptake value expressed in %IA/g ± SD. The dotted curves indicate the 95 % confidence interval

Back to article page